## Supplementary data

## EGFR targeted nanobody functionalized polymeric micelles loaded with mTHPC for selective photodynamic therapy

Yanna Liu<sup>a</sup>, Luca Scrivano<sup>a</sup>, Julia Denise Peterson<sup>a</sup>, Marcel H.A.M. Fens<sup>a</sup>, Irati Beltrán Hernández<sup>a,b</sup>, Bárbara Mesquita<sup>a</sup>, Javier Sastre Toraño<sup>c</sup>, Wim E. Hennink<sup>a</sup>, Cornelus F. van Nostrum<sup>a</sup>, and Sabrina Oliveira<sup>a,b</sup>.

<sup>a</sup>Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

<sup>b</sup>Division of Cell Biology, Department of Biology, Utrecht University, Utrecht, the Netherlands.

<sup>c</sup>Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

\* Corresponding author: S.Oliveira@uu.nl, Phone: +31 63 410 3460, Fax: +31 30 251 7839





**Figure S1.** <sup>1</sup>H NMR spectra of the PCL<sub>n</sub> oligomers, intermediate products and final PCL<sub>n</sub>-PEG/PCL<sub>n</sub>-PEG-Mal block copolymers (n=9, 15 and 23).



Scheme S1. Synthesis and Cy7 labeling of PCL-PDTC-PEG.



**Figure S2.** (A) UV-Vis spectra of PCL<sub>9</sub>-PEG-Mal, Mal-PEG-NH<sub>2</sub>, PCL<sub>9</sub>-PEG, PEG-NH<sub>2</sub> in DCM at a polymer concentration of 5 mg/mL and (B) calibration curve of Mal-PEG-NH<sub>2</sub> in DCM.



Figure S3. GPC chromatograms of PCL<sub>9</sub>-OH and PCL<sub>9</sub>-PEG recorded by refractive index (RI) detector.



**Figure S4.** (A) Calibration curve of Cy7-maleimide in DCM, recorded at 755.5 nm and (B) GPC curves of Cy7maleimide, PCL<sub>18</sub>-PDTC<sub>7.5</sub>-PEG polymer and Cy7-labeled PCL<sub>18</sub>-PDTC<sub>7.5</sub>-PEG polymer, recorded at 700 nm by UV/vis detector.



**Figure S5.** (A-B) LC-ESI-TOF-MS spectra of native EGa1 (A) and SATA modified EGa1 (B) at a 1:5 molar ratio of EGa1 to SATA, respectively. The inset of theoretical mass in (B) correlated with the molecular weight of 0 to 2 SATA molecules conjugated to one EGa1 molecule. (C) the number of sulfhydryls (-SH) per native EGa1, reduced EGa1 and SATA modified EGa1 after 1:5 molar incubation ratio of EGa1 to SATA based on Ellman's assay.



**Figure S6.** SDS-PAGE silver staining of SATA-EGa1 and micelles composed of 9:1 mixtures of PCL<sub>n</sub>-PEG and PCL<sub>n</sub>-PEG-Mal incubated with/without (protected) SATA-EGa1. A is the protein ladder; lane B represents SATA-modified EGa1; lanes C-E are  $P_n$  micelles incubated with protected EGa1-SATA (n=9 (C), n=15 (D), n=23 (E)); lanes F-H display  $P_n$  micelles alone (n=9 (F), n=15 (G), n=23 (H)).



**Figure S7.** EGFR expression in A431 and HeLa cells as determined by flow cytometry, using cells that were incubated with an antibody against the EGFR receptor. \*\*\* represents p < 0.001.



**Figure S8.** (A) Representative confocal fluorescence microscopic images of A431 and HeLa cells incubated with free mTHPC and mTHPC containing a 9 fold excess of free EGa1 (named free mTHPC+EGa1) for 7 h at 37 °C. mTHPC concentration was 38  $\mu$ g/mL, corresponding to a concentration using 5wt% mTHPC-loaded micelles as used in Figure 2. Cell nuclei are stained in blue with Hoechst, while fluorescence of mTHPC is represented in red. Scale bars indicate 20  $\mu$ m. The images were taken using the same parameters in both cells (excitation times requied

for images were 25 msec). (B) Quantification of fluorescence intensity of mTHPC ( $\lambda_{ex}$  405 nm,  $\lambda_{em}$  676 nm) in A431 and HeLa cells by ImageJ. The quantified fluorescence intensity was normalized by the intensity of mTHPC in A431 cells and by the number of cells.

## S1 Cytotoxicity of empty micelles

EGa1-P<sub>n</sub> micelles without mTHPC loading and their corresponding non-targeted micelles at a fixed polymer concentration of 10 mg/mL in PBS (prepared as described in Section 2.4 and 2.5) were employed to assess the cytotoxicity of the empty micelles on A431 and HeLa cells, following the similar protocol in photo-cytotoxicity study (described in section 2.9) with a slight adjustment of the volume ratio between the medium and the micellar dispersions, depending on the predetermined polymer concentration. For instance, to get a final polymer concentration of 4 mg/mL, 80  $\mu$ L of micellar dispersions was added to 120  $\mu$ L medium and the cells were cultured for 24 h at 37 °C. Cell viability was determined by MTS assay.



**Figure S9.** Cytotoxicity assessed by MTS assay of empty targeted EGa1- $P_n$  and non-targeted  $P_n$  micelles composed of 2 and 4 mg/mL PCL<sub>n</sub>-PEG/PCL<sub>n</sub>-PEG-Mal (9:1) polymer on A431 and HeLa cells after 24 h incubation at 37 °C (n = 9, 15 and 23, respectively). N=3.

**Table S1.** Loading efficiency (LE) and loading capacity (LC) of mTHPC loaded in  $P_{23}$  micelles decorated with EGa1 nanobody (targeted) or cysteines only (non-targeted).

Feed ratio of mTHPC — to polymer(wt%)	P <sub>23</sub> micelles (non-targeted)		EGa1-P <sub>23</sub> micelles (targeted)	
	LE%	LC%	LE%	LC%
1%	65	0.3	65	0.3
2%	94	1.8	93	1.8
4%	94	3.6	95	3.6
6%	83	4.7	83	4.7
8%	72	5.4	72	5.4
10%	76	7.1	76	7.1



**Figure S10.** SDS-PAGE silver staining of mTHPC-loaded EGa1-conjugated and unconjugated micelles (*i.e.* EGa1-P<sub>23</sub> micelles (lanes I, G, E, C) and P<sub>23</sub> micelles (lanes H, F, D, B), respectively) with 2, 4, 6, 8 wt% mTHPC, respectively, after 10 washings with PBS using centrifugation with Vivaspin-6 tubes along with native EGa1 control (J). Lane A represents a protein ladder.

**Table S2.** EC<sub>50</sub> of free mTHPC and mTHPC loaded in micelles (1 mg/mL polymer) on A431 and HeLa cells after 7 h incubation.

	EC <sub>50</sub> (μg/mL)	
	A431	HeLa
P <sub>23</sub> micelles	38.3±1.9	29.2±2.6
EGa1-P <sub>23</sub> micelles	$10.4\pm0.7$	$28.5 \pm 1.8$
Competition	48.3±3.1	32.7±1.0
Free mTHPC	$1.6 \pm 0.1$	1.2 <sup>a</sup>
Free mTHPC+EGa1	1.7±0.1	1.3ª
r c D < 0.1		

a SD < 0.1.



**Figure S11.** Fluorescence emission spectrum of singlet oxygen sensor green reagent in free mTHPC solution or its solvent only; in mTHPC in  $P_{23}$  micelles, or in PBS pH 7.4. Measurements performed after 0, 1, 3 or 6 min of illumination with a filtered white light source at 645-665 nm at a fluence rate of 5 mW/cm<sup>2</sup>.



**Figure S12.** Fluorescence intensity ( $\lambda_{ex}$  420 nm,  $\lambda_{em}$  655 nm) as a function of time at 37 °C in PBS (A) and DMSO (B); Foscan<sup>®</sup> and micelles of 10 mg/mL with 5wt% loading amounts were prepared and diluted 10× in PBS or DMSO, to obtain the final mTHPC concentration of 40 µg/mL.



**Figure S13.** (A-B) The log-concentration of free mTHPC (A) and Cy7 labeled (EGa1)-P<sub>23</sub> micelles (B) loaded with mTHPC (A) in blood overtime upon tail vein administration in A431 tumor-bearing Balb/c mice (0.3 mg mTHPC per kg bodyweight of the mouse, *i.e.*, ~6  $\mu$ g mTHPC). Blood samples taken at different time points were used to quantify the percentage of mTHPC and the corresponding Cy7 labeled micelles of the injected dose (%ID) present in systemic circulation. Data are presented as mean ± SD, N= 4.